RB1 and neoplasm: The question remains whether SCLC already existed in the tumor tissue itself and manifested itself as a consequence of the applied tyrosine kinase therapy or whether this histological transformation is the result of molecular changes at the level of the RB1 gene, which is the key “trigger” that leads to histological changes in the tumor tissue [57].